Feature | May 14, 2014

Leadless Pacemaker Showing Promising Results After One Year

Follow-up results for Nanostim presented in late-breaking clinical trial presentation at Heart Rhythm 2014

May 14, 2014 — Vivek Reddy, M.D., director of arrhythmia services for The Mount Sinai Hospital, reported promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Reddy presented the one-year LEADLESS study data findings during a late-breaking clinical trial presentation on Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim leadless pacemaker at hospitals in Prague and in Amsterdam. The findings, which assessed device performance and patient outcomes through 12 months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace or communicate with the pacemaker.

"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology, and our results show the leadless pacemaker is comparable to traditional pacemakers," says Reddy, who is the study's co-investigator and chairman of its steering committee. "Our latest findings further support the promising performance and safety of this minimally invasive, nonsurgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials."

In February, Reddy was the first to implant the leadless pacemaker in the United States. The multicenter clinical trial LEADLESS II aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the United States and Canada.

The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than 10 percent the size of a traditional pacemaker. It works by closely monitoring the heart's electrical rhythms, and if the heartbeat is too slow it provides electrical stimulation therapy to regulate it. More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year.

In comparison to a conventional pacemaker, the leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction.

The LEADLESS study was funded by St. Jude Medical, manufacturer of the Nanostim pacemaker. Reddy receives financial compensation as a consultant and advisory board member for St. Jude Medical. In addition, in 2013 he received one-time financial compensation from St. Jude Medical in the form of an option buyout relating to St. Jude Medical's acquisition of Nanostim.

For more information: www.mountsinai.org, www.sjm.com

Related Content

INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing| December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Boston Scientific, HeartLogic Heart Failure Diagnostic Service, MultiSENSE trial data, AHA Scientific Sessions 2016
News | Heart Failure| November 18, 2016
Boston Scientific recently announced results from the first clinical trial evaluating the performance of the HeartLogic...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation| November 15, 2016
Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than...
Medtronic, Claria MRI Quad CRT-D SureScan, FDA approval
Technology | Cardiac Resynchronization Therapy Devices (CRT)| November 15, 2016
Medtronic plc  has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI Quad Cardiac...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Sponsored Content | Videos | Heart Valve Technology| November 14, 2016
William Abraham, M.D., FACC, discusses advances in heart failure device treatment technologies at the Transcatheter C
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing| November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
transcatheter aortic valve replacement, pacemakers, implantation, post-TAVR implantation, worse outcomes, study
News | EP Lab| November 09, 2016
Patients who undergo minimally invasive heart valve replacement, known as transcatheter aortic valve replacement (TAVR...
Overlay Init